Fw: FDA Requires New Safety Measures for Oral Sodium Phosphate Products to Reduce Risk of Acute Kidney Injury

[Guest guest]

From: U.S. Food & Drug Administration (FDA) <fda@...>

Subject: FDA Requires New Safety Measures for Oral Sodium Phosphate Products to

Reduce Risk of Acute Kidney Injury

wooleeacre@...

Date: Thursday, December 11, 2008, 12:08 PM

#yiv428251103 {

font-size:12px;font-family:arial, verdana,

sans-serif;font-weight:normal;font-style:normal;}

#yiv428251103 .physicalAddress {

color:gray;font-size:10px;font-family:arial, verdana,

sans-serif;font-weight:100;}

FDA Requires New Safety Measures for Oral Sodium Phosphate Products to Reduce

Risk of Acute Kidney Injury

Thu, 11 Dec 2008 13:32:00 -0600

Today, the U.S. Food and Drug Administration announced that it will add a Boxed

Warning to the prescription oral sodium phosphate products Visicol and OsmoPrep

to warn consumers about the risk of acute phosphate nephropathy (a type of acute

kidney injury). Patients routinely take OSP products to cleanse the bowel before

a colonoscopy (colon examination) and other medical procedures.